All In Biotech

Drug Trial Radar · NCT05670951

Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

Last checked: Nov 20, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Feb 27, 2025

Primary completion

Nov 2027

Study completion May 2029

Sponsor

Lead sponsor
Elgan Pharma Ltd.Industry
Sponsor type
Industry
First posted
Jan 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 day, up to 5 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the effect of ELGN-2112 on intestinal malabsorption in preterm infants.

Conditions

  • Intestinal Malabsorption

Interventions

  • ELGN-2112Drug

    Human insulin \[rDNA\]

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Numbers of days to achieve full enteral feedingTime frame: 28 days or discharge from hospital

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Laniado Hospital

    Netanya, Israel · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.